Key result
Early aspirin discontinuation and transition to P2Y12 monotherapy is supported in high bleeding risk patients post-PCI.
Why the study?
Advancements in PCI devices and recognition of post-PCI bleeding risks have motivated investigation into modulating the intensity and duration of DAPT.
Does early aspirin discontinuation and transitioning to P2Y12 inhibitor monotherapy improve outcomes in patients with ACS or CCS undergoing PCI?
Population
ACS or CCS patients undergoing PCI stratified by HBR features
Design
Review
Authors
Loading...
May support early aspirin discontinuation in high-bleeding-risk post-PCI patients; leaves open confirmation by dedicated RCTs.
Does early aspirin discontinuation and transitioning to P2Y12 inhibitor monotherapy improve outcomes in patients with ACS or CCS undergoing PCI?
A patient-centered approach favoring early aspirin discontinuation and P2Y12 inhibitor monotherapy is supported by current evidence for post-PCI patients, particularly those at high bleeding risk.
Landi et al. (2025) conducted a review in Acute coronary syndromes (ACS) or chronic coronary syndromes (CCS) undergoing PCI. Early aspirin discontinuation and P2Y12 inhibitor monotherapy vs. Standard dual antiplatelet therapy was evaluated. Early aspirin discontinuation and transitioning to P2Y12 inhibitor monotherapy is supported by current evidence, particularly in patients with high bleeding risk after percutaneous coronary intervention.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: